Cash-pay patients who want quick, message-based access to branded GLP-1s with published starting prices and who don't plan to use insurance.
- Starting price
- $39 first month membership
- Consult model
- Asynchronous (questionnaire + messaging)
- Prescriber
- MD/DO + NP/PA
- Labs
- Billed separately
- Insurance
- Cash pay
- Availability
- Unconfirmed
- Cancellation
- Self-serve online
- Founded
- 2017 · San Francisco, CA
Pricing
The Weight Loss Membership is $39 for the first month, then auto-renews at $149/mo, and medication is billed separately. Listed starting prices: Wegovy pill from $149/mo, Wegovy pen from $199/mo, Zepbound KwikPen from $299/mo and Foundayo from $149/mo. The oral non-GLP-1 kits start at $69/mo, but only on a 10-month plan paid upfront. Medication fees are FSA/HSA-eligible; the membership fee is not.
Prices as listed on October 17, 2026. They change often; confirm at checkout.
What we like
- Offers FDA-approved branded GLP-1s (Wegovy pill/pen, Ozempic, Zepbound, Foundayo) with starting prices shown on the site
- Low $39 first month of membership
- Medication fees are FSA/HSA-eligible
- Non-GLP-1 oral medication kits available as a lower-cost option
Watch out for
- Membership ($149/mo after month one) is billed on top of medication
- Doesn't use insurance for its weight-loss program
- Active FTC lawsuit (July 2026) over health-data sharing and billing/cancellation practices, plus a Sept 2025 FDA warning letter over compounded semaglutide claims
- Trustpilot score of 2.9 from about 9,600 reviews
Cancelling
Per Hims support search snippets, you cancel in the app (Profile > Subscriptions > Manage subscription > turn off auto-renew) at least two days before the next billing date, and cancellation takes effect at the end of the billing period. Ending the membership also ends the medication plan. The FTC's July 2026 complaint alleges subscriptions were difficult to cancel and that customers were charged once they submitted intake forms; Hims calls the claims baseless.
Where it is available
Hims says GLP-1s are 'not yet available in all 50 states' but publishes no state list; the platform overall operates in all 50 states (not Puerto Rico)
- 2025-09 FDA warning letters (hims.com and forhers.com) said compounded semaglutide claims such as 'Same active ingredient as Ozempic and Wegovy' were misleading, so the products were misbranded. Source ↗
- 2026-02 Novo Nordisk sued Hims over compounded semaglutide products; the suit was dismissed without prejudice in March 2026 alongside a new Novo-Hims collaboration. Source ↗
- 2026-07 FTC, with Utah and Los Angeles County, sued Hims & Hers (N.D. Cal.), alleging it shared health data with ad platforms and used deceptive billing and cancellation practices; the company calls the claims baseless. Source ↗
- 2026-08 Securities class action (Velanki v. Hims & Hers Health, N.D. Cal. 3:26-cv-09313) filed after the FTC suit; allegations unproven. Source ↗
